REL and lymphoma: Moreover, treatment with the PI3K inhibitor GDC-0941/Pictilisib, selectively targeted the Eμ-Myc/c-Rel−/− lymphomas, while having no effect on their WT equivalents (Figure 3, Supplementary Figure S7).